Eisai Co., Ltd. (TYO:4523)
4,737.00
-53.00 (-1.11%)
At close: Dec 2, 2025
Eisai Revenue
Eisai had revenue of 197.36B JPY in the quarter ending September 30, 2025, with 0.70% growth. This brings the company's revenue in the last twelve months to 804.39B, up 6.79% year-over-year. In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B with 6.42% growth.
Revenue (ttm)
804.39B
Revenue Growth
+6.79%
P/S Ratio
1.66
Revenue / Employee
73.68M
Employees
10,917
Market Cap
1.34T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
| Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
| Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
| Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
| Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |
Eisai News
- 15 hours ago - Eisai : Etalanetug Demonstrates Reduction Of EMTBR-tau243 In Phase Ib/II Alzheimer's Study - Nasdaq
- 16 hours ago - Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 - PRNewsWire
- 3 days ago - Biogen, Eisai File In Japan To Make Leqembi A Weekly At-Home Alzheimer's Shot - Benzinga
- 4 days ago - Eisai Announces Filing Of New Drug Application For Leqembi In Japan - Nasdaq
- 7 days ago - Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status - Benzinga
- 14 days ago - Eisai to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - PRNewsWire
- 26 days ago - Q2 2026 Eisai Co Ltd Earnings Presentation Transcript - GuruFocus
- 26 days ago - Eisai Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha